Transition from Conventional Drugs to Promising Drugs for Primary Biliary Cholangitis

Kazufumi Dohmen*

Internal Medicine, Chihaya Hospital, Japan

Submission: March 09, 2017; Published: March 24, 2017

*Corresponding author: Kazufumi Dohmen, Internal Medicine, Chihaya Hospital, 2-30-1 Chihaya Higashi-ku, Fukuoka 813-8501, Japan, Tel: +81-92-661-2211; Fax: +81-92-685-0411; E-mail: dohmen-kzf@cool.odn.ne.jp

Abstract

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic cholestatic liver disease characterized by chronic, non-suppurative, destructive cholangitis that eventually leads to cholestasis, fibrosis, cirrhosis and subsequent hepatic failure and death if left untreated. The only available therapeutic agent for PBC is ursodeoxycholic acid (UDCA), which has been demonstrated to delay the development of fibrosis as well as improve patient survival without the need for liver transplantation. However, not all patients achieve a complete biochemical response to UDCA.

Fibrate is a fibric acid derivative used in the treatment of hypercholesterolemia and hyperglyceridemia, and it has been incidentally noted to cause a decrease in serum liver biochemical markers. The proposed mechanism of action of fibric acid derivatives involves regulation of the expression of various kinds of lipids and proteins, as well as cell proliferation, through the activation of peroxisome proliferator-activated receptor-α. Obeticholic acid, a first-in-class alternative farnesoid X receptor agonist, is a semi-synthetic bile acid analogue of 6α-ethylchenodeoxycholic acid that is nearly 100-fold more potent than chenodeoxycholic acid. The efficacy of both fibrate and beticholic acid in addition to UDCA in asymptomatic PBC patients who did not respond well to UDCA alone has been confirmed. Further progress in the study of newer drugs that are effective for symptomatic PBC patients is expected in the future.

Keywords: Primary biliary cholangitis; Fibrate; Histology; Therapy

Ursodeoxycholic Acid

The first known available therapeutic agent for primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA), which has been demonstrated to delay the development of fibrosis as well as improve survival in patients without the need for liver transplantation [1-3]. The optimal dosage of UDCA is 13-15mg/kg/day and it is the standardized treatment for PBC. However, not all patients achieve a complete biochemical response to UDCA, and 10-20% will progress to cirrhosis or require liver transplantation. The most important merits of UDCA are lower costs and few adverse effects.

Budesonide

Budesonide is a glucocorticoid receptor/pregnane X receptor (PXR) agonist. Combination therapy of budesonide and UDCA was able to ameliorate the plasma biochemical index of hepatic function and hepatic histology, particularly in PBC patients with hepatic fibrosis, whereas the treatment effectiveness of UDCA alone was principally seen in laboratory results [4].

Methotrexate

In patients who responded inadequately to UDCA, methotrexate noticeably improves hepatic enzyme tests and hepatic histology [5]. However, of the immunosuppressive drugs that have been tested for the treatment of PBC, azathioprine, cyclosporine and methotrexate were not found to improve patient survival [6,7].

Fibrates

Fibrate is a fibric acid derivative used in the treatment of hypercholesterolemia and hyperglyceridemia that has been incidentally noted to cause a decrease in the levels of serum liver biochemical markers. The proposed mechanism of action of fibric acid derivatives involves the regulation of cell proliferation and the expression level of various lipids and proteins via the activation of peroxisome proliferator-activated receptor (PPAR)-α [8-10]. Therefore, fibric acid is referred to as a “PPAR-α agonist”. Bezafibrate activates all three isoforms of human PPAR (PPAR-α, PPAR-δ, and PPAR-γ) at similar concentrations (i.e., 50, 20 and 60
Obeticholic Acid

Obeticholic acid (OCA) is a semi-synthetic bile acid analogue of 6α-ethyl-chenodeoxycholic acid that is nearly 100-fold more potent than chenodeoxycholic acid (CDCA) and is a powerful first-class alternative FXR agonist derived from primary human bile acid CDCA, the natural endogenous FXR agonist. A randomized, controlled clinical trial showed that treatment with OCA observably decreased the serum concentrations of γ-GTP, ALP, and ALT in patients with primary biliary cirrhosis (PBC) who had an inadequate response to UDCA, in comparison with placebo [23]. OCA is so expensive that improving cost-effectiveness could be a challenge.

Newer drug expectations and appropriate timing of administration of drugs

The efficacy of UDCA, fibrates or other medicines for symptomatic PBC patients has not been confirmed. Newer drugs that are effective for symptomatic PBC patients are clearly needed. Moreover, the use of drugs is expected to be categorized according to the stage of PBC and response to drugs could be predictive of the outcomes of PBC.

References


This work is licensed under Creative Commons Attribution 4.0 License
DOI: 10.19080/ARGH.2017.04.555634

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php